Article
Immunology
Joanna Kaminska, Violetta Dymicka-Piekarska, Robert Chrzanowski, Karol Sawicki, Anna J. Milewska, Justyna Zinczuk, Marzena Tylicka, Marek Jadeszko, Zenon Mariak, Ewa M. Kratz, Joanna Matowicka-Karna, Johannes Kornhuber, Piotr Lewczuk, Olga M. Koper-Lenkiewicz
Summary: Research has shown that in patients with un-ruptured brain aneurysms, both the IL-6 Quotient and CSF IL-6 concentration are significantly higher, especially in those with multiple aneurysms. This indicates that IL-6 may serve as a biomarker for UIA formation.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Oncology
Tsunenori Yamamoto, Ryouichi Tsunedomi, Masao Nakajima, Nobuaki Suzuki, Shin Yoshida, Shinobu Tomochika, Ming Xu, Yuki Nakagami, Hiroto Matsui, Yukio Tokumitsu, Yoshitaro Shindo, Yusaku Watanabe, Michihisa Iida, Shigeru Takeda, Shoichi Hazama, Tsuyoshi Tanabe, Tatsuya Ioka, Yoshinobu Hoshii, Akifumi Kiyota, Hitoshi Takizawa, Yutaka Kawakami, Tomio Ueno, Hiroaki Nagano
Summary: This study investigated the relationship between an immunosuppressive state and patient prognosis in colorectal cancer (CRC) by evaluating the levels of interleukin (IL)-6 in both the systemic and tumor microenvironment. The results showed that elevated serum IL-6 levels were associated with elevated stromal IL-6 levels and a poor prognosis for CRC patients. In addition, tumor-infiltrating immune cells expressing IL-6 were primarily composed of myeloid cells and rarely lymphoid cells.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Clinical Neurology
Jan-Baptist Belge, Linda Van Diermen, Bernard Sabbe, Jan Moens, Manuel Morrens, Violette Coppens, Philippe de Timary, Eric Constant, Kristof Vansteelandt, Pascal Sienaert, Didier Schrijvers
Summary: This study found that the improvement in psychomotor functions in depressed patients after ECT is related to the decrease in IL-6 levels. Higher baseline IL-6 levels positively correlated with higher severity of psychomotor retardation in these patients.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Immunology
Elettra Capogna, Leiv Otto Watne, Oystein Sorensen, Carlijn Jamila Guichelaar, Ane Victoria Idland, Nathalie Bodd Halaas, Kaj Blennow, Henrik Zetterberg, Kristine Beate Walhovd, Anders Martin Fjell, Didac Vidal-Pineiro
Summary: Concentrations of pro-inflammatory cytokines IL-6 and IL-8 increase with age and in Alzheimer's disease (AD). It is unclear whether these cytokine concentrations in the central nervous system can predict brain and cognitive changes over time, and whether this relationship is influenced by core AD biomarkers. This study followed 219 cognitively healthy older adults with baseline CSF measures of IL-6 and IL-8 for up to 9 years, and found that higher CSF IL-8 levels were associated with better memory performance over time, particularly when CSF p-tau and p-tau/Aβ-42 levels were lower. Higher CSF IL-6 levels were also related to less CSF p-tau changes over time. These findings support the hypothesis that upregulation of IL-6 and IL-8 in the brain may have a neuroprotective role in cognitively healthy older adults with lower AD pathology burden.
BRAIN BEHAVIOR AND IMMUNITY
(2023)
Article
Clinical Neurology
Simone Hjaeresen, Tobias Sejbaek, Marcus Axelsson, Helle Vinslov-Jensen, Sif Klovedal Mortensen, Gorm Pihl-Jensen, Lenka Novakova, Julie Damgaard Rosgaard Christensen, Christian Bonde Pedersen, Bo Halle, Frantz Rom Poulsen, Jette Lautrup Frederiksen, Mengliang Zhang, Eirikur Benedikz, Jan Lycke, Zsolt Illes, Asa Fex Svenningsen
Summary: This study found that levels of HTRA1 in cerebrospinal fluid significantly increased in multiple sclerosis patients, and disease modifying therapies were able to decrease these levels. ROC analysis showed that HTRA1 levels could distinguish healthy controls from MS patients, demonstrating potential biomarker value.
JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Aletta van den Bosch, Nina Fransen, Matthew Mason, Annemieke Johanna Rozemuller, Charlotte Teunissen, Joost Smolders, Inge Huitinga
Summary: This study aimed to investigate the association between white matter lesion activity, acute axonal damage, and axonal density in MS with CSF neurofilament light chain (NfL) levels. The results showed that active and mixed white matter MS lesions with foamy microglia exhibited high acute axonal damage and correlated with elevated CSF NfL levels. These findings support the use of CSF NfL as a biomarker to monitor inflammatory demyelinating lesion activity with axonal damage in MS.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Clinical Neurology
Alba Trislan-Noguero, Eva Borras, Marta Molero-Luis, Tessa Wassenberg, Tessa Peters, Marcel M. Verbeek, Michel Willemsen, Thomas Opladen, Kathrin Jeltsch, Roser Pons, Beat Thony, Gabriella Horvath, Zuhal Yapici, Jennifer Friedman, Keith Hyland, Guillermo E. Agosta, Eduardo Lopez-Laso, Rafael Artuch, Eduard Sabido, Angels Garcia-Cazorla
Summary: This study conducted proteomic studies in cerebrospinal fluid samples of patients with monoamine defects and identified 4 novel biomarkers, shedding new light on the consequences of early dopaminergic deprivation in the developing brain.
MOVEMENT DISORDERS
(2021)
Article
Multidisciplinary Sciences
Marko Petrzalka, Eva Meluzinova, Jana Libertinova, Hana Mojzisova, Jitka Hanzalova, Petra Rockova, Martin Elisak, Silvia Kmetonyova, Jan Sanda, Ondrej Sobek, Petr Marusic
Summary: By assessing the biomarkers in the cerebrospinal fluid and serum obtained early after the onset of multiple sclerosis, this study found that the IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 may serve as prognostic biomarkers in the early stages of the disease.
Article
Clinical Neurology
Vincenzo Donadio, Zerui Wang, Alex Incensi, Giovanni Rizzo, Enrico Fileccia, Veria Vacchiano, Sabina Capellari, Martina Magnani, Cesa Scaglione, Michelangelo Stanzani Maserati, Patrizia Avoni, Rocco Liguori, Wenquan Zou
Summary: This study demonstrates that both immunofluorescence and RT-QuIC show high diagnostic accuracy in distinguishing synucleinopathies from non-synucleinopathies, with immunofluorescence displaying better value and optimal reproducibility. Immunofluorescence exhibits good agreement with RT-QuIC in synucleinopathies in both skin and CSF.
Article
Clinical Neurology
Vincenzo Donadio, Zerui Wang, Alex Incensi, Giovanni Rizzo, Enrico Fileccia, Veria Vacchiano, Sabina Capellari, Martina Magnani, Cesa Scaglione, Michelangelo Stanzani Maserati, Patrizia Avoni, Rocco Liguori, Wenquan Zou
Summary: The study demonstrates that both immunofluorescence and RT-QuIC have high diagnostic accuracy in distinguishing synucleinopathies from non-synucleinopathies, with immunofluorescence showing higher diagnostic accuracy and a good level of agreement with RT-QuIC in both skin and CSF.
Article
Neurosciences
Marcos Pais, Julia Loureiro, Vagner do Vale, Marcia Radanovic, Leda Talib, Florindo Stella, Orestes Forlenza
Summary: Analysis of CSF biomarkers was able to differentiate between AD, MCI, and NC, yet clinical-biological mismatches were observed in a non-negligible proportion of cases.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
Marie-Christine Reinert, Brenda Huppke, Hannah Hummel-Abmeier, Wiebke Stark, Jutta Gaertner, Peter Huppke
Summary: The results of this study have important implications: pretreatment sNfL levels are a valuable biomarker for underlying disease activity in pediatric patients with MS; pretreatment sNfL levels in pediatric patients with MS have a predictive value for the response to first-line therapy and the necessity of future therapy escalation; high sNfL levels during a relapse are associated with poor recovery in this age group.
Article
Clinical Neurology
Federico Verde, Edoardo Nicolo Aiello, Ilaria Milone, Eleonora Giacopuzzi Grigoli, Antonella Dubini, Antonia Ratti, Barbara Poletti, Nicola Ticozzi, Vincenzo Silani
Summary: This study compared the distribution of T +/- profiles among A+patients with MCI and dementia. The results showed that A+T+ profiles were predominant in both groups, contradicting the common notion of A+T- profiles being more prevalent in MCI patients.
NEUROLOGICAL SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Luciana de Brito Falcao, Anacelia Gomes de Matos, Deysi Viviana Tenazoa Wong, Roberto Cesar Pereira Lima-Junior, Priscila da Silva Mendonca, Ana Patricia Nogueira Aguiar, Roberta Taiane Germano de Oliveira, Emanna Odilia de Castro Lima, Ronald Feitosa Pinheiro, Silvia Maria Meira Magalhaes
Summary: The study found that patients with MDS had lower levels of IL-33, especially in those with more advanced stages and worse prognosis. There was no significant correlation between IL-33 and IL-6 levels. These results highlight the close association between immunological disorders and the pathogenesis of MDS.
Article
Neurosciences
Adriel S. Moraes, Vinicius O. Boldrini, Alliny C. Dionete, Marilia D. Andrade, Ana Leda F. Longhini, Irene Santos, Amanda D. R. Lima, Veronica A. P. G. Silva, Rafael P. C. Dias Carneiro, Raphael P. S. Quintiliano, Breno B. Ferrari, Alfredo Damasceno, Fernando Pradella, Alessandro S. Farias, Charles P. Tilbery, Renan B. Domingues, Carlos Senne, Gustavo B. P. Fernandes, Felipe von Glehn, Carlos Otavio Brandao, Carla R. A. V. Stella, Leonilda M. B. Santos
Summary: The study found that NTZ treatment significantly decreased NfL levels in CSF of MS patients, increased sHLA-G levels in serum, and enhanced tolerogenic and migratory functions of pDCs in peripheral blood.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2021)
Article
Clinical Neurology
Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Ekaterina Manuilova, Alexander Jethwa, Tobias Bittner, Udo Eichenlaub, Ivonne Suridjan, Gwendlyn Kollmorgen, Matthias Riepe, Christine A. F. von Arnim, Hayrettin Tumani, Klaus Hager, Fedor Heidenreich, Niklas Mattsson-Carlgren, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Summary: This study explores the use of fully automated plasma assays to measure amyloid beta pathology and predict future Alzheimer's disease dementia. The results show that A beta 42/A beta 40 is the best biomarker for discriminating A beta-positive versus A beta-negative participants. Combining A beta 42/A beta 40 with p-tau181 and ApoE4 significantly improves diagnostic accuracy. This study provides promising evidence for implementing plasma biomarkers in clinical trials and routine clinical practice.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Christina Rabe, Tobias Bittner, Alexander Jethwa, Ivonne Suridjan, Ekaterina Manuilova, Michel Friesenhahn, Erik Stomrud, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Summary: This study evaluated the clinical performance and robustness of plasma Aβ(42)/Aβ(40) as a prescreening tool for Alzheimer's disease. It found that there were misclassifications caused by measurement errors and pre-analytical errors, and suggested that other blood biomarkers may be easier to implement as robust prescreening tools.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Alexa Pichet Binette, Shorena Janelidze, Nicholas Cullen, Jeffrey L. Dage, Randall J. Bateman, Henrik Zetterberg, Kaj Blennow, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: This study found that creatinine and body mass index are associated with certain plasma biomarker levels, but they do not have clinically relevant confounding effects for the majority of individuals.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Colin Groot, Ruben Smith, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Anika Wuestefeld, Laura E. M. Wisse, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Shorena Janelidze, Olof Strandberg, Rik Ossenkoppele, Oskar Hansson
Summary: Among amyloid-positive individuals, tau discordance predicts increased rates of tau accumulation on PET, but not increased cognitive decline or cortical thinning. Individuals with this biomarker profile may be an interesting target group for intervention in early Alzheimer's disease.
Article
Clinical Neurology
Shorena Janelidze, Divya Bali, Nicholas J. Ashton, Nicolas R. Barthelemy, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Yingxin He, Anna Orduna Dolado, Gallen Triana-Baltzer, Michael J. Pontecorvo, Henrik Zetterberg, Hartmuth Kolb, Manu Vandijck, Kaj Blennow, Randall J. Bateman, Oskar Hansson
Summary: Plasma phospho-tau species, especially p-tau217, show promise as blood-based biomarkers for Alzheimer's disease. This study compared the performance of different assays for p-tau181, p-tau217, and p-tau231 in detecting abnormal A beta status and predicting progression to Alzheimer's dementia. The mass spectrometry-based p-tau217 (p-tau217(WashU)) demonstrated the best performance, while several immunoassays, including p-tau217(Lilly), p-tau217(Janss), p-tau181(ADx), and p-tau181(WashU), showed high accuracy in both outcomes.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alexander F. Santillo, Antoine Leuzy, Michael Honer, Maria Landqvist Waldo, Pontus Tideman, Luke Harper, Tomas Ohlsson, Svenja Moes, Lucia Giannini, Jonas Jogi, Colin Groot, Rik Ossenkoppele, Olof Strandberg, John van Swieten, Ruben Smith, Oskar Hansson
Summary: The uptake of [F-18]RO948 is not significantly increased in the majority of FTD patients, with the exception of specific MAPT mutations. The observed tracer retention does not overlap with the cortical atrophy, expected pattern of atrophy, or verified protein pathology distribution.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Endocrinology & Metabolism
Khazar Ahmadi, Joana B. Pereira, David Berron, Jacob Vogel, Silvia Ingala, Olof T. Strandberg, Shorena Janelidze, Frederik Barkhof, Josef Pfeuffer, Linda Knutsson, Danielle van Westen, Sebastian Palmqvist, Henk J. M. M. Mutsaerts, Oskar Hansson
Summary: This study investigated the role of decreased cerebral blood flow in Alzheimer's disease and found that tau tangles and neurodegeneration are more closely connected with GM-CBF changes than A beta pathology.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
(2023)
Article
Clinical Neurology
Scott Ayton, Shorena Janelidze, Pawel Kalinowski, Sebastian Palmqvist, Abdel Ali Belaidi, Erik Stomrud, Anne Roberts, Blaine Roberts, Oskar Hansson, Ashley Ian Bush
Summary: This study investigates the association between iron, inflammation, apolipoprotein, and Alzheimer's disease. It suggests that iron is closely associated with apolipoprotein E and tau pathology, and plays different roles in different stages of the disease, correlating with cognitive deterioration.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Diana I. Bocancea, Anna L. Svenningsson, Anna C. van Loenhoud, Colin Groot, Frederik Barkhof, Olof Strandberg, Ruben Smith, Renaud La Joie, Howard J. Rosen, Michael J. Pontecorvo, Gil D. Rabinovici, Wiesje M. van der Flier, Oskar Hansson, Rik Ossenkoppele
Summary: The mechanisms of resilience against tau pathology in Alzheimer's disease spectrum are not well understood. This longitudinal study investigates the factors that contribute to cognitive and brain resilience against tau pathology and finds that education is the most important determinant of resilience. However, resilience may be depleted in advanced stages of the disease.
Article
Clinical Neurology
Anika Wuestefeld, Alexa Pichet Binette, David van Berron, Nicola Spotorno, Danielle van Westen, Erik Stomrud, Niklas Mattsson-Carlgren, Olof Strandberg, Ruben Smith, Sebastian Palmqvist, Trevor Glenn, Svenja Moes, Michael Honer, Konstantinos Arfanakis, Lisa L. Barnes, David A. Bennett, Julie A. Schneider, Laura E. M. Wisse, Oskar Hansson
Summary: This study found that tau pathology, independent of amyloid-beta, may exist outside of the medial temporal lobe and affect cognition and brain structures. These findings have implications for understanding the spread of tau in Alzheimer's disease and suggest the potential use of tau-targeting treatments.
Article
Medicine, Research & Experimental
Gemma Salvado, Rik Ossenkoppele, Nicholas J. Ashton, Thomas G. Beach, Geidy E. Serrano, Eric M. Reiman, Henrik Zetterberg, Niklas Mattsson-Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
Summary: Several promising plasma biomarkers for Alzheimer's disease have been developed, but their neuropathological correlates are not fully understood. This study investigates the associations between multiple plasma biomarkers and amyloid and tau neuropathological measures. The results suggest that plasma p-tau217 and A beta 42/40 might be an optimal combination for assessing Alzheimer's-related pathology.
EMBO MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Dovile Poceviciute, Bodil Roth, Nina Schultz, Cristina Nunez-Diaz, Shorena Janelidze, Anders Olofsson, Oskar Hansson, Malin Wennstrom
Summary: Pancreas-derived islet amyloid polypeptide (IAPP) crosses the blood-brain barrier and co-deposits with amyloid beta (A beta) in brains of type 2 diabetes (T2D) and Alzheimer's disease (AD) patients. Levels of IAPP antibodies were not altered in AD patients compared with controls, but significantly lower IAPP(O)-IgA levels were found in APOE4 carriers, which is linked to the AD pathology. Plasma IAPP-Ig levels, especially IAPP-IgA, correlated with cognitive decline and other AD-related factors in APOE4 non-carriers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg, Oskar Hansson
Summary: This study investigated the relationship between A beta 42/A beta 40 ratios and cerebral A beta pathology using App knock-in mouse models. The results showed a negative association between A beta 42/A beta 40 ratios and cerebral A beta plaque burden in App(NL-F/NL-F) mice, with stronger correlations observed in CSF compared to serum. Additionally, the decline in A beta 42/A beta 40 ratios in CSF and serum occurred after the deposition of A beta aggregates in the brain reached significance. However, no similar changes were observed in App(NL/NL) mice.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Medicine, General & Internal
John R. Sims, Jennifer A. Zimmer, Cynthia D. Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Paul Solomon, Stephen Salloway, Liana G. Apostolova, Oskar Hansson, Craig Ritchie, Dawn A. Brooks, Mark Mintun, Daniel M. Skovronsky
Summary: This study evaluated the efficacy and adverse events of donanemab, an antibody treatment for Alzheimer's disease. The findings showed that donanemab significantly slowed disease progression in patients with early symptomatic Alzheimer's disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cell Biology
Nicolas R. Barthelemy, Benjamin Saef, Yan Li, Brian A. Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvado, Shorena Janelidze, Chihiro Sato, Vitaliy Ovod, Rachel L. Henson, Anne M. Fagan, Tammie L. S. Benzinger, Chengjie Xiong, John C. Morris, Oskar Hansson, Randall J. Bateman, Suzanne E. Schindler
Summary: CSF tau phosphorylation at T217 and T205 sites is a better marker for Alzheimer's disease pathology than current tests.